fda warning bpc 157 not approved peptide safety Banned: Key Facts on the Latest Decision The Food and Drug Administration's

It is not approved by the FDA for fat loss or any other use, and any clinical application falls under the supervision of a licensed medical provider

This is especially important to avoid if they have been sick

Protocol overview: BPC-157 administered via subcutaneous injection, locally near the affected joint Standard dosing range: 200500 mcg per injection session Treatment duration: 48 weeks of active treatment Follow-up assessments: 6 months and 12 months post-treatment Patients were evaluated using validated pain scales (VAS and KOOS scores) and functional mobility assessments at each follow-up point

They monitored IGF-1 levels, tracked insulin sensitivity, and conducted oral glucose tolerance tests